Biotech unusual volume stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), BioDelivery Sciences International (NASDAQ:BDSI), ImmunoCellular Therapeutics (NYSEMKT:IMUC), Anika Therapeutics (NASDAQ:ANIK)



AbbVie may now consider a takeover of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), a $411 million company, to expand in that market, Redmond said. Shares of Achillion rallied (ACHN:US) as much as 67 percent yesterday. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was 47.57% in last session and finished the day at $4.25. Traded volume was 47.79million shares in the last session and the average volume of the stock remained 1.42million shares. The beta of the stock remained 1.89. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) insider ownership is 13.04%.

Merck & Co has agreed to buy Idenix Pharmaceuticals Inc (NASDAQ:IDIX) for $3.85bn in a deal aimed at bolstering its position in the hotly contested race to develop a new generation of hepatitis C treatments. The US drugmaker is vying with rivals including Gilead Sciences, Johnson & Johnson and AbbVie for share of a market forecast to reach at least $20bn of annual sales by the end of this decade. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) rose 229.05 percent to $23.79 Monday on volume of 41.11million shares. The intra-day range of the stock was $23.530 to $24.21. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) has a market capitalization of $3.59billion.

Roth Capital lifted their price target on shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to $15.50 in a research note issued on Monday. The firm currently has a “buy” rating on the stock. Roth Capital’s price target suggests a potential upside of 55.00% from the company’s current price. BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s stock on June 09, 2014 reported a decrease of -1.50% to the closing price of $9.85. Its fifty two weeks range is $3.86 -$10.35. The total market capitalization recorded $477.46million. The overall volume in the last trading session was 3.18million shares. In its share capital, BDSI has 48.44million outstanding shares.

ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) on June 1 announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago. When overall survival (OS) and progression-free survival (PFS) were assessed in pre-specified patient subgroups, results favored treatment with ICT-107 over control in HLA-A2 patients within each of the two major MGMT subgroups (unmethylated and methylated). On Monday, shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) dropped -1.67% to close the day at $1.18. Company monthly performance is recorded as 5.36%. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) quarterly revenue growth is -9.92%.

Analysts at Singular Research upped their price target on shares of Anika Therapeutics, Inc (NASDAQ:ANIK) from $43.50 to $54.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. Singular Research’s price target would indicate a potential upside of 15.14% from the stock’s previous close. Anika Therapeutics, Inc. (NASDAQ:ANIK) stock performance was 2.15% in last session and finished the day at $48.86. Traded volume was 1.33million shares in the last session and the average volume of the stock remained 344.38K shares. The beta of the stock remained 1.79. Anika Therapeutics, Inc. (NASDAQ:ANIK) insider ownership is 2.30%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone